[1] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012[J] . Eur J Cancer, 2013, 49(6):1374-1403. [2] Mauricio Z, Baptista D, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer[J] . Human Pathlogy, 2016, 47(1):78-84. [3] Li B, VanRoey M, Wang C, et al. Anti- programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors[J] . Clin Cancer Res, 2009, 15(5):1623-1634. [4] Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1(B7-H1)expression and the immune tumor microenvironment in primary and metastatic breast carcinomas[J] . Human Pathology, 2016, 47(1):52-63. [5] Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J] . Cellular Immunology, 2014, 290(1):72-79. [6] Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity[J] . Autoimmunity Reviews, 2013, 12(11):1091-1100. [7] Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD- L1 blockade[J] . Proc Natl Acad Sci USA, 2002, 99(19):12293-12297. [8] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apotosis:a potential mechanism of immune evasion[J] . Nat Med, 2008, 8(8):793-800. [9] Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer[J] . J Immunother, 2012, 35(2):169-178. [10] Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)[J] . Proc Natl Acad Sci USA, 2008, 105(52):20852-20857. [11] Tuchscherer M, Kanitz E, Otten W, et al. Effects of prenatal stress on cellular and humoral immune responses in neonatal pigs[J] . Veterinary Immunology and Immunopathology, 2002, 86(3):195-203. [12] Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model[J] . Int J Oncol, 2009, 35(4):741-749. [13] Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1(PD-L1)T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma:correlation with important high-risk prognostic factors[J] . Neoplasia, 2006, 8(3):190-198. [14] D’Addio F, Riella LV, Mfarrej BG, et al. The link between the PD-L1 costimulatory pathway and Th17 in fetomaternal tolerance[J] . J Immunol, 2011, 187(9):4530-4541. [15] Liu H, Bakthavatsalam R, Meng Z, et al. PD-L1 signal on liver dendritic cells is critical for Foxp3+CD4+CD25 + Treg and liver tolerance induction in mice[J] . Transplant Proc, 2013, 45(5):1853-1855. [16] Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4+ CD25+Foxp3+Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV[J] . J Clin Invest, 2009, 119(3):551-564. [17] Beswick EJ, Pinchuk IV, Das S, et al. Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+CD25+Foxp3+ regulatory T cells[J] . Infect Immune, 2007, 75(9):4334-4341. [18] Sumimoto H, Kawakami Y. Lentiviral vector-mediated RNAi and its use for cancer research[J] . Future Oncol, 2007, 3(6):655-664. [19] Katayama K, Koichiro W, Miyoshi H, et al. RNAinterfering approach forclarifying the PPAR pathway using lentiviral vectors expressing short hairpin RNA[J] . FEBS Letters, 2004, 560(3):178-182. [20] 李跃萍, 宋丽萍, 邱曙东, 等. 慢病毒载体在肿瘤基因治疗中的应用[J] . 现代肿瘤医学, 2006, 14(12):1615-1617. [21] Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector[J] . Science, 1996, 272(5259):263-267. [22] 罗望, 张泓, 许淼, 顾林, 等. 慢病毒——基因转移的潜在新载体[J] . 江苏药学与临床研究, 2006, 14(6):366-371. |